Jorge Duconge to United States
This is a "connection" page, showing publications Jorge Duconge has written about United States.
Connection Strength
0.198
-
Duconge J, Rua?o G. Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: lessons from warfarin. Pharmacogenomics. 2018 07 01; 19(11):875-881.
Score: 0.083
-
Duconge J. The case of biotech-derived product equivalence: much ado about nothing? Curr Clin Pharmacol. 2006 May; 1(2):147-56.
Score: 0.036
-
El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci. 2021 01; 14(1):268-276.
Score: 0.024
-
Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodr?guez-Maldonado J, Duconge J, Rua?o G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019 06; 13(8):649-661.
Score: 0.022
-
Claudio-Campos K, Duconge J, Cadilla CL, Rua?o G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther. 2015 Jun; 30(2):87-105.
Score: 0.017
-
Miranda-Massari JR, Gonz?lez MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jim?nez Ramirez FJ, Cintr?n K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, V?zquez A. [Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):60-6.
Score: 0.017